[1] Brown SR, Lee S, Brown TA, et al. Effect of race on thyroid cancer care in an equal access healthcare system[J]. Am J Surg, 2010, 199(5): 685-689. DOI:10.1016/j.amjsurg.2010.01.020.
[2] Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474. DOI:10.1245/s10434-010-0985-4.
[3] Slijepcevic N, Zivaljevic V, Marinkovic J, et al. Retrospective evaluation of the incidental finding of 403 papillary thyroid microcarcinomas in 2466 patients undergoing thyroid surgery for presumed benign thyroid disease[J]. BMC Cancer, 2015, 15(1): 330. DOI:10.1186/s1288501513524.
[4] Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area[J]. World J Surg, 2010, 34(6): 1214-1221. DOI:10.1007/s00268-009-0375-x.
[5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. DOI:10.3322/caac.21254.
[6] Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1): 2835. DOI:10.1007/s0026800903030.
[7] Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons[J]. World J Surg, 2011, 35(1): 111121. DOI:10.1007/s00268-010-0832-6.
[8] Wu AW, Nguyen C, Wang MB. What is the best treatment for papillary thyroid microcarcinoma?[J]. Laryngoscope, 2011, 121(9): 1828-1829. DOI:10.1002/lary.22033.
[9] Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroidPrognostic significance of lymph node metastasis and multifocality[J]. Cancer, 2003, 98(1): 31-40. DOI:10.1002/cncr.11442.
[10] Hay ID, Grant CS, Van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50year period[J]. Surgery, 1992, 112(6): 1139-1146.
[11] Hay ID, Hutchinson ME, GonzalezLosada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60year period[J]. Surgery, 2008, 144(6): 980-987. DOI:10.1016/j.surg.2008.08.035.
[12] So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections[J]. Surgery, 2010, 148(3): 526-531. DOI:10.1016/j.surg.2010.01.003.
[13] Tae K, Ji YB, Cho SH, et al. Initial experience with a gasless unilateral axillobreast or axillary approach endoscopic thyroidectomy for papillary thyroid microcarcinoma: comparison with conventional open thyroidectomy[J]. Surg Laparosc Endosc Percutan Tech, 2011, 21(3): 162-169. DOI:10.1097/SLE.0b013e318218d1a4.
[14] Gao W, Liu L, Ye G, et al. Application of minimally invasive videoassisted technique in papillary thyroid microcarcinoma[J]. Surg Laparosc Endosc Percutan Tech, 2013, 23(5): 468-473. DOI:10.1097/SLE.0b013e318274b611.
[15] Lee S, Ryu HR, Park JH, et al. Early surgical outcomes comparison between robotic and conventional open thyroid surgery for papillary thyroid microcarcinoma[J]. Surgery, 2012, 151(5): 724-730. DOI:10.1016/j.surg.2011.12.013.
[16] Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma[J]. Eur J Endocrinol, 2012, 167(2): 267-275. DOI:10.1530/EJE120105.
[17] Pisanu A, Reccia I, Nardello O, et al. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors[J]. World J Surg, 2009, 33(3): 460-468. DOI:10.1007/s00268-008-9870-8. |